Brickworks (ASX:BKW) maintains an impressive 47-year streak
Nick Sundich, March 23, 2023
Brickworks (ASX:BKW) has achieved a feat that few other ASX companies have: maintaining or increasing dividends for 47 years in a row. It released 1HY23 results this morning and recorded an NPAT of $410m.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
BKW records a solid result
BKW generated $584m in revenue (up 13%), $569m in EBIT (up 26%) and a $410m underlying NPAT (up 24%). It paid a dividend of 23c per share, yielding 1.9% on an annualised basis and thereby keeping the streak alive.
Ironically, this was not achieved merely through the company’s core brick-making operatings.
Property helps
Brickworks has a strategic stake in Washington Soul Pattinson (ASX:SOL) and also interests in industrial property. A $301m sale of Oakdale East into the Industrial Joint Venture Trust delivered earnings of $263m and boosted the Net Asset Value of Property Trusts to $2.2bn.
Turning to Building Products, North American EBITDA was up 16% to $14m but down 6% to $50m in Australia. The company blamed a backlog of work from government stimulus, labour market tightness and supply chain issues.
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Analysts aren’t optimistic about iron ore prices in 2025, will they be right and what will it mean for iron ore stocks?
In which direction will iron ore prices in 2025 go? Chinese trade data would suggest upwards, and indeed prices jumped…
Paradigm Biopharmaceuticals’ flagship drug Zilosul will be in Phase 3 in 2025
Paradigm Biopharmaceuticals (ASX:PAR) has been listed for nearly a decade with the goal of bringing its flagship drug pentosan polysulfate…
Findi (ASX:FND): Its quadrupled in 12 months off the back of financial services in India
Until Findi (ASX:FND) came along, there were practically no ASX companies making money from India (or at least not many…